MPP+ toxicity and plasma membrane dopamine transporter: Study using cell lines expressing the wild-type and mutant rat dopamine transporters

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1404, Issue 3, 1998, Pages 305-313

  Kitayama, Shigeo ^a   Mitsuhata, Chieko ^a   Davis, Steven ^b   Wang, Jia Bei ^b   Sato, Tomoyuki ^a   Morita, Katsuya ^a   Uhl, George R ^b   Dohi, Toshihiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Dopamine; Efflux; MPP+; Neurotoxin; Parkinsonism; Transporter

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; COCAINE; COMPLEMENTARY DNA; DOPAMINE; DOPAMINE TRANSPORTER; NEUROTOXIN; TRITIUM;

ANIMAL CELL; ARTICLE; CELL MEMBRANE TRANSPORT; CELL STRAIN COS1; CONCENTRATION RESPONSE; DOPAMINERGIC NERVE CELL; HELA CELL; HUMAN; HUMAN CELL; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL MEMBRANE; CELL SURVIVAL; COCAINE; COS CELLS; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HERBICIDES; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RATS; TETRAZOLIUM SALTS; TRANSFECTION;

EID: 0032538010     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(98)00071-8     Document Type: Article

References (19)

1. [1] J.A. Javitch, R.J. D'Amato, S.M. Strittmatter, S.H. Snyder, Proc. Natl. Acad. Sci. USA 82 (1985) 2173-2177.
2. [2] K. Chiba, A.J. Trevor, N. Castagnoli, Biochem. Biophys. Res. Commun. 128 (1985) 1228-1232.
3. [3] R.A. Mayer, M.V. Kindt, R.E. Heikkila, J. Neurochem. 47 (1986) 1073-1079.
4. [4] J. Willoughby, R.F. Cowburn, J.A. Hardy, V. Glover, M. Sandler, J. Neurochem. 52 (1989) 627-631.
5. [5] K.F. Tipton, T.P. Singer, J. Neurochem. 61 (1993) 1191-1206.
6. [6] G.R. Uhl, Trend. Neurosci. 15 (1992) 265-268.
7. [7] S. Kitayama, T. Dohi, Jpn. J. Pharmacol. 72 (1996) 195-208.
8. [8] S. Kitayama, S. Shimada, G.R. Uhl, Ann. Neurol. 32 (1992) 109-111.
9. [9] C. Pifl, B. Giros, M.G. Caron, J. Neurosci. 13 (1993) 4246-4253.
10. [10] C. Pifl, O. Hornykiewicz, B. Giros, M.G. Caron, J. Pharmacol. Exp. Ther. 277 (1996) 1437-1443.
11. [11] S. Kitayama, K. Morita, T. Dohi, Eur. J. Pharmacol. 309 (1996) 107-109.
12. [12] S. Kitayama, K. Morita, T. Dohi, Neurosci. Lett. 211 (1996) 132-134.
13. [13] S. Kitayama, J.B. Wang, G.R. Uhl, Synapse 15 (1993) 58-62.
14. [14] S. Kitayama, S. Shimada, H. Xu, L. Markham, D.M. Donovan, G.R. Uhl, Proc. Natl. Acad. Sci. USA 89 (1992) 7782-7785.
15. [15] C. Mitsuhata, S. Kitayama, K. Morita, D. Vandenbergh, G.R. Uhl and T. Dohi, Mol. Brain Res., in press.
16. [16] M. Ishiyama, M. Shiga, K. Sasamoto, M. Mizoguchi, P.-G. He, Chem. Pharm. Bull. 41 (1993) 1118-1122.
17. [17] A. Giovanni, B.-A. Sieber, R.E. Heikkila, P.K. Sonsalla, J. Pharmacol. Exp. Ther. 270 (1994) 1000-1007.
18. [18] A. Giovanni, P.K. Sonsalla, R.E. Heikkila, J. Pharmacol. Exp. Ther. 270 (1994) 1008-1014.
19. [19] Y. Liu, A. Roghani, R.H. Edwards, Proc. Natl. Acad. Sci. USA 89 (1992) 9074-9078.